Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer

H. Cure, V. Chevalier, D. Pezet, J. Bousquet, C. Focan, F. Levi, C. Garufi, J. Chipponi, P. Chollet

Research output: Contribution to journalArticle

Abstract

Forty three patients with metastatic colorectal cancer (MCC) received a daily administration of 5-fluorouracil (600 mg/m2/d at the first course, 700 mg/m2/d at the second and 800 mg/m2/d at the third course), and l-folinic acid (150 mg/m2/d) or dl-folinic acid (300 mg/m2/d) both chronomodulated from 22:00 to 10.00 am with peak delivery rate at 4.00 for 5 days every 21 days. Only severe mucositis and diarrhea occurred in 19 courses (5.7% Gr 3; 0.6% Gr 4) in 14 patients. Objective response (OR) was evaluated in 40 patients because of one toxicity and two early progressions. No OR was observed in the 15 previously-treated patients versus 28.5% (8/28) partial responses in chemotherapy naïve patients; overall the median survival was 13 months. These results without toxicity and with low OR rate indicate the necessing of a more intensive treatment and confirm the place of oxaliplatin in the chemotherapy of MCC.

Original languageEnglish
Pages (from-to)4649-4653
Number of pages5
JournalAnticancer Research
Volume20
Issue number6 C
Publication statusPublished - 2000

Keywords

  • 5-fluorouracil
  • Chronotherapy
  • Folinic acid
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Cure, H., Chevalier, V., Pezet, D., Bousquet, J., Focan, C., Levi, F., Garufi, C., Chipponi, J., & Chollet, P. (2000). Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer. Anticancer Research, 20(6 C), 4649-4653.